Cost and public reimbursement of cancer medicines in the UK and the Republic of Ireland.

David E O'ReillyRonan McLaughlinCian RonayneAnne Marie De FreinBojan MacanovicRyan W ChuSinead A NoonanRoisin M ConnollyDerek G PowerRichard M BamburySeamus O'ReillyDearbhaile Catherine Collins

Published in: Irish journal of medical science (2022)

Our study highlights that many licensed systemic anticancer treatments are not currently reimbursed in ROI/UK. The high cost of these medicines is independent of the presence of an OS benefit. Collaboration between regulatory agencies, governments and industry partners is needed to ensure health expenditure is directed towards the most effective treatments.

Keyphrases

healthcare
mental health
public health
papillary thyroid

cross sectional
squamous cell
health information
squamous cell carcinoma

young adults
risk assessment
childhood cancer

hepatitis c virus
hiv testing
electronic health record